Drug Approval | October 09, 2022
Dipharma receives regulatory authorization for the new line at Its cGMP pilot plant
The company increases its efficiency and is able to face the growing demand for its services.
The company increases its efficiency and is able to face the growing demand for its services.
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Sause will become CEO Roche Diagnostics and a member of the Corporate Executive Committee effective 1 January 2023.
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
Mirabegron Extended-Release Tablets, 25 mg and 50 mg, had estimated annual sales of US $2.4 billion in US
Sildenafil for Oral Suspension (RLD Revatio) had estimated annual sales of US $64 million in the US
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
Transformation to pure-play Innovative Medicines company nears completion
Subscribe To Our Newsletter & Stay Updated
